APA (7th ed.) Citation

PM, F., M, B., A, F., FR, L., D, B., A, K., . . . S, G. (2020). Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: A dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. The Lancet. Infectious diseases, 20(7), 816. https://doi.org/10.1016/S1473-3099(20)30160-2

Chicago Style (17th ed.) Citation

PM, Folegatti, et al. "Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-vectored Vaccine: A Dose-escalation, Open-label, Non-randomised, Uncontrolled, Phase 1 Trial." The Lancet. Infectious Diseases 20, no. 7 (2020): 816. https://doi.org/10.1016/S1473-3099(20)30160-2.

MLA (9th ed.) Citation

PM, Folegatti, et al. "Safety and Immunogenicity of a Candidate Middle East Respiratory Syndrome Coronavirus Viral-vectored Vaccine: A Dose-escalation, Open-label, Non-randomised, Uncontrolled, Phase 1 Trial." The Lancet. Infectious Diseases, vol. 20, no. 7, 2020, p. 816, https://doi.org/10.1016/S1473-3099(20)30160-2.